Novartis AG
NYSE:NVSDrug Manufacturers - General
-$3.38 today
- Market cap
- $293.13B
- Beta
- 0.49
- P/E (TTM)
- 20.7
- EPS (TTM)
- $7.06
- Dividend yield
- 3.13%
Volume 2.75M
Average 1.56M
NVS Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Novartis AGNYSE: NVS
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation outflow shrinks to $0
Q2 FY2026 stock-based compensation was $0, compared with $267M a year earlier. Trailing-twelve-month stock-based compensation was $571M.
Context
- Stock-based compensation amounted to 0.0% of revenue in FY2025, down 2.0 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $142.75M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 1.04B | +20.7% |
| FY2023 | 2023-12-31 | 865M | +9.4% |
| FY2022 | 2022-12-31 | 791M | +13.0% |
| FY2021 | 2021-12-31 | 700M | — |
Stock-Based Compensation vs competitors
How NVS compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -45.9% is the 7th highest of 8, against a peer median of +7.6%.
- Stock-based compensation amounts to 1.0% of revenue for NVS, versus a peer median of 1.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.42B USD | +11.0% | +6.0% | 1.4% | |
| LTM Jun 2026 | $976M USD | +4.5% | +12.5% | 1.5% | |
| LTM Jun 2026 | $947M USD | +14.9% | -2.9% | 1.5% | |
| LTM Jun 2026 | $892M USD | +12.5% | — | 1.3% | |
| LTM Jun 2026 | $571M USD | -45.9% | — | 1.0% | |
| LTM Jun 2026 | $553M USD | +4.3% | +6.6% | 1.1% | |
| LTM Jun 2026 | $460M USD | -47.2% | +11.6% | 1.5% | |
| LTM Jun 2026 | €184M EUR | +7.6% | — | 0.4% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Jun 2026 | DKK 0 DKK | — | — | 0.0% | |
| LTM Jun 2026 | £0 GBP | — | — | 0.0% | |
| Peer median (excluding NVS) | — | +7.6% | +6.6% | 1.2% | |
Competitors are the stored peer set for NVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 22.91B | 6.05B | 8.57B | 11.94B | 14.06B |
| Depreciation & Amortization | 5.6B | 6.71B | 8.28B | 6.07B | 5.35B |
| Deferred Income Tax | 1.63B | 1.13B | 551M | 1.7B | (361.84M) |
| Stock-Based Compensation | 700M | 791M | 865M | 1.04B | 0 |
| Change in Working Capital | (73M) | (796M) | (369M) | (706M) | (3.08B) |
| Accounts Receivables | (352M) | (397M) | (1.5B) | (931M) | (1.13B) |
| Inventory | (102M) | (560M) | (546M) | (225M) | 34.17M |
| Accounts Payables | (111M) | (181M) | 479M | (105M) | (274.4M) |
| Other Working Capital | 492M | 342M | 1.2B | 555M | (1.71B) |
| Other Non-Cash Items | (15.68B) | 359M | (3.44B) | (2.43B) | 3.27B |
| Operating Cash Flow | 15.07B | 14.24B | 14.46B | 17.62B | 19.24B |
| Capital Expenditures | (2.56B) | (2.24B) | (2.75B) | (3.81B) | (1.56B) |
| Acquisitions (Net) | 20.46B | (864M) | (3.57B) | (3.83B) | (3.01B) |
| Purchases of Investments | (16.59B) | (34.81B) | (747M) | (3.65B) | (304.55M) |
| Sales of Investments | 2.74B | 39.49B | 11.6B | 3.7B | 2.19B |
| Other Investing Activities | (1.34B) | (1.43B) | (624M) | (2.38B) | 140.72M |
| Investing Cash Flow | 4.21B | 1.47B | 5.6B | (7.51B) | (4.9B) |
| Debt Repayment | (5.67B) | (2.59B) | (1.94B) | 4.39B | 2.72B |
| Common Stock Issued | 0 | 0 | 0 | 0 | 27.14M |
| Common Stock Repurchased | (3.06B) | (10.65B) | (8.72B) | (8.33B) | (9.26B) |
| Dividends Paid | (7.37B) | (7.51B) | (7.26B) | (7.62B) | (7.86B) |
| Other Financing Activities | (169M) | 181M | 3.63B | (177M) | (577.95M) |
| Financing Cash Flow | (16.26B) | (20.56B) | (14.28B) | (11.74B) | (14.94B) |
| Effect of Forex Changes | (266M) | (32M) | 100M | (298M) | 579.07M |
| Net Change in Cash | 2.75B | (4.89B) | 5.88B | (1.93B) | (24M) |
| Free Cash Flow | 12.52B | 12B | 11.71B | 13.81B | 17.69B |
Novartis AG
NYSE:NVS
Intrinsic Alpha fair value
Locked
Current Price
$155.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.